HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection
Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection With Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study
Sponsor: Gilead Sciences
Listed as NCT02309918, this PHASE2 trial focuses on Acute Hepatitis C and remains completed. Sponsored by Gilead Sciences, it has been updated 8 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
- Hannover Medical School
- HepNet Study House, German Liverfoundation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berlin, Germany , Bonn, Germany , Düsseldorf, Germany , Essen, Germany , Frankfurt, Germany , Freiburg im Breisgau, Germany , Hamburg, Germany , Hanover, Germany , Heidelberg, Germany , Herne, Germany and 8 more locations